Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease

Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease

IntroductionGraves’ disease is an autoimmune disorder caused by auto-antibodies against the thyroid stimulating hormone receptor (TSHR). Overstimulation of the TSHR induces hyperthyroidism and thyroid eye disease (TED) as the most common extra thyroidal manifestation of Graves’ disease. In TED, the...

Full description

Bibliographic Details
Main Authors:	Anne Gulbins, Mareike Horstmann, Simone Keitsch, Matthias Soddemann, Barbara Wilker, Gregory C. Wilson, Ryan Zeidan, Gary D. Hammer, Anke Daser, Nikolaos E. Bechrakis, Gina-Eva Görtz, Anja Eckstein
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Endocrinology
Subjects:	bone marrow linsitinib autoimmunity inflammation small molecule IGF-1R antagonist GD: Graves’ disease thyroid eye disease (TED)
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1252727/full

Similar Items

Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease
by: Anne Gulbins, et al.
Published: (2023-06-01)

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
by: Michael Oeverhaus, et al.
Published: (2023-04-01)

Sphingolipids in thyroid eye disease
by: Anne Gulbins, et al.
Published: (2023-04-01)

Editorial: News in Graves’ orbitopathy: patients management and treatments
by: Giulia Lanzolla, et al.
Published: (2023-08-01)

Significance of thyroperoxidase and thyroglobulin antibodies in medically treated Graves’ disease
by: Stefan Matei Constantinescu, et al.
Published: (2023-12-01)

Emerging therapies in the medical management of thyroid eye disease
by: Alisha Kamboj, et al.
Published: (2023-12-01)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
by: Lilly H. Wagner, et al.
Published: (2022-11-01)

Systematic review of ocular surface treatments in the setting of thyroid eye disease
by: Anthony Stephen Wong, et al.
Published: (2024-06-01)

EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?
by: Giulia Bresciani, et al.
Published: (2019-05-01)

Effects of linsitinib on M22 and IGF:1-treated 3D spheroids of human orbital fibroblasts
by: Fumihito Hikage, et al.
Published: (2025-01-01)

Gut Microbiome and the Role of Metabolites in the Study of Graves’ Disease
by: Haihua Liu, et al.
Published: (2022-02-01)

The association of race with thyroid eye disease presentation and outcomes
by: Diane Wang, et al.
Published: (2024-01-01)

High IgG4 serum concentration is associated with active Graves orbitopathy
by: Michał Olejarz, et al.
Published: (2023-03-01)

Graves’ Disease and Rheumatoid Arthritis: A Bidirectional Mendelian Randomization Study
by: Dide Wu, et al.
Published: (2021-08-01)

Modulating gut microbiota in a mouse model of Graves’ orbitopathy and its impact on induced disease
by: Sajad Moshkelgosha, et al.
Published: (2021-02-01)

New Therapeutic Horizon of Graves’ Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine
by: Qiongyao He, et al.
Published: (2022-04-01)

Type 1 Insulin-Like Growth Factor Receptor Nuclear Localization in High-Grade Glioma Cells Enhances Motility, Metabolism, and In Vivo Tumorigenesis
by: Ayelen Martin, et al.
Published: (2022-04-01)

Clinically practical pharmacometrics computer model to evaluate and personalize pharmacotherapy in pediatric rare diseases: application to Graves' disease
by: Britta Steffens, et al.
Published: (2023-05-01)

Utility of colour flow doppler ultrasonography to differentiate gestational transient thyrotoxicosis and graves disease in pregnancy
by: Vijay Sheker Reddy Danda, et al.
Published: (2024-01-01)

Psychiatric complications in Graves’ disease
by: Mats Holmberg, et al.
Published: (2024-02-01)

Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormone Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases – Why Not This One?
by: Amy M. FitzPatrick
Published: (2022-06-01)

Commentary: Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial
by: Madhukar Mittal, et al.
Published: (2024-02-01)

Targeted immunotherapies for Graves’ thyroidal & orbital diseases
by: Alan Chun Hong Lee, et al.
Published: (2025-03-01)

Dermopathy of Graves′ disease: Clinico-pathological correlation
by: Sagili Vijaya Bhaskar Reddy, et al.
Published: (2012-01-01)

Smoking enhances proliferation, inflammatory markers, and immunoglobulins in peripheral blood mononuclear cells from Graves’ patients
by: Bushra Shahida, et al.
Published: (2024-05-01)

Graves’ ophthalmopathy – thyroid eye disease
by: Dagna Siedlecka, et al.
Published: (2019-08-01)

Precision Medicine in Graves’ Disease and Ophthalmopathy
by: Giusy Elia, et al.
Published: (2021-10-01)

Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease
by: Julia Ryniecka, et al.
Published: (2025-01-01)

Diosgenin From Dioscorea Nipponica Rhizoma Against Graves’ Disease—On Network Pharmacology and Experimental Evaluation
by: Jingxin Xin, et al.
Published: (2022-01-01)

What kind of therapeutic solutions for Graves’ disease does modern medicine propose? - a review of the literature
by: Natalia Woś, et al.
Published: (2023-05-01)

Selenium and Graves’ Disease
by: Vahab Fatourechi, et al.
Published: (2024-10-01)

Acute Pericarditis as an Uncommon Presentation of Graves’ Disease
by: Abdullah Al-Futaisi, et al.
Published: (2022-03-01)

Graves’ ophtalmopathy
by: Satvinder Bakshi
Published: (2022-02-01)

Two adolescent patients with coexistent Graves' disease and Moyamoya disease in Korea
by: Chong Kun Cheon, et al.
Published: (2014-06-01)

Predicting remission of Graves' disease following treatment with antithyroid drugs
by: Natalya V. Drogashevskaya, et al.
Published: (2023-04-01)

The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
by: LingHong Huang, et al.
Published: (2022-05-01)

Radioiodine treatment for graves’ disease: a 10-year Australian cohort study
by: Erin Fanning, et al.
Published: (2018-12-01)

Cross-sectional study of thyroid associated orbitopathy in a South African thyroid clinic
by: Sandra De Vasconcelos, et al.
Published: (2025-02-01)

Graves disease and atrial fibrillation
by: Bello-Espinosa Ariel, et al.
Published: (2010-06-01)

Hearing loss and pathogenesis in Graves' disease
by: HU Xiaoxia, et al.
Published: (2022-03-01)